Abstract
Tatton-Brown-Rahman syndrome (TBRS; OMIM 615879), also known as the DNMT3A-overgrowth syndrome, is an overgrowth intellectual disability syndrome first described in 2014 with a report of 13 individuals with constitutive heterozygous variants. Here we have undertaken a detailed clinical DNMT3A study of 55 individuals with variants, including the 13 de novo DNMT3A previously reported individuals. An intellectual disability and overgrowth were reported in >80% of individuals with TBRS and were designated major clinical associations. Additional frequent clinical associations (reported in 20-80% individuals) included an evolving facial appearance with low-set, heavy, horizontal eyebrows and prominent upper central incisors; joint hypermobility (74%); obesity (weight ³2SD, 67%); hypotonia (54%); behavioural/psychiatric issues (most frequently autistic spectrum disorder, 51%); kyphoscoliosis (33%) and afebrile seizures (22%). One individual was diagnosed with acute myeloid leukaemia in teenage years. Based upon the results from this study, we present our current management for individuals with TBRS Keywords DNMT3A, Tatton-Brown-Rahman, overgrowth, intellectual disability .
Results
All 55 individuals had an intellectual disability: 18% had a mild intellectual disability (10/55); 65% had a moderate intellectual disability (36/55) and 16% had a severe intellectual disability (9/55) ( Table 1 , Figure 2 ). Behavioural/psychiatric issues were reported in 51% (28/55) individuals and included combinations of autistic spectrum disorder (20 individuals); anxiety (three individuals); neurodevelopmental regression (four individuals two of whom regressed in teenage years); psychosis/schizophrenia (three individuals); aggressive outbursts (two individuals), and bipolar disorder (two individuals) ( Table 1) .
Postnatal overgrowth (defined as height and/or head circumference at least two standard deviations above the mean (≥2SD) 2,13 , was reported in 83% (44/53) individuals. Obesity, with a weight ≥2SD, was reported in 67% (34/51). The range of individual postnatal heights, head circumferences and weights is shown in Table 1 and Figure 3 . The mean birth weight was 1.3SD with a range from -1.1 to 4.0 SD. We had limited data for birth head circumference and birth length, but their mean was 2.3SD and 1.6SD, respectively.
There were some shared, but subtle, facial characteristics often only becoming apparent in early adolescence (Figure 4a and b) . These included low-set, horizontal thick eyebrows; narrow palpebral fissures; coarse features and a round face. The two upper central incisors were also frequently enlarged and prominent.
Additional clinical features reported in greater than 20% (≥ 11) individuals included: joint hypermobility (74%, 37/50); hypotonia (54%, 28/52); kyphoscoliosis (33%, 18/55) and afebrile seizures (22%, 12/55) ( Table 1 ). In addition, short, widely spaced toes were frequently mentioned, but the overall frequency is unclear as we did not specifically ask about feet/toes on the clinical proforma (Figure 4c ).
Clinical features reported in at least two but fewer than 20% individuals included cryptorchidism (six individuals); ventriculomegaly (four individuals) and Chiari malformation (three individuals). In addition, a range of cardiac anomalies (including atrial septal defect, mitral/tricuspid valve incompetence, patent ductus arteriosus, aortic root enlargement and atrio-ventricular re-entry tachycardia) were reported in nine individuals. However, of note, two individuals with cardiac anomalies (patent ductus arteriosus, COG1961 and COG2006) were identical twins with DNMT3A whole gene deletions encompassing >40 genes. The patent ductus arteriosus in these individuals may, therefore, be attributable to twinning, alternative genes in the deleted region or the combined effect of a number of deleted genes.
Acute myeloid leukaemia (AML), AML-FAB (French-AmericanBritish classification) type M4, was diagnosed in one individual Full clinical details from the 55 individuals are provided in Table 1 .
Discussion
We have evaluated clinical data from 55 individuals with de novo constitutive DNMT3A variants to define the phenotype of TBRS. An intellectual disability (most frequently in the moderate range) and overgrowth (defined as height and/or head circumference ≥2SD above the mean) were reported in ≥80% of individuals and have been designated major clinical associations. Frequent clinical associations, reported in 20-80% of individuals with constitutive DNMT3A variants, included joint hypermobility, obesity, hypotonia, behavioural/psychiatric issues (most frequently autistic spectrum disorder), kyphoscoliosis and afebrile seizures. In addition, many individuals had a characteristic facial appearance although this may only be recognizable in adolescence.
TBRS overlaps clinically with other OGID syndromes including Sotos syndrome (OMIM 117550), Weaver syndrome (OMIM 277590), Malan syndrome (OMIM 614753) and the OGID syndrome due to CHD8 gene variants 2 . However, TBRS is more frequently associated with increased weight than the other OGID syndromes and may be distinguishable through recognition of the associated facial features, and absence of the facial gestalt of other OGID syndromes.
Somatic DNMT3A variants are known to drive the development of adult AML and myelodysplastic syndrome and over half of the DNMT3A somatic variants target a single residue, the p.Arg882 residue [14] [15] [16] [17] . AML, diagnosed in childhood, has now been identified in two individuals with (likely) constitutive DNMT3A variants from a total of 77 (1/55 individuals in the current study and 1/22 previously reported individuals) 7 . One of these individuals had a de novo c.2644CT p.(Arg882Cys) DNMT3A variant and developed AML at 15 years of age 7 . The variant was present in genomic DNA extracted from the patient's remission blood sample and skin fibroblasts. The second individual had a c.2204A>C p.(Tyr735Ser) DNMT3A variant identified in DNA obtained at 5 years of age and developed AML at the age of 12 years. Whilst these data indicate that AML may be a rare association of TBRS, currently the numbers of individuals reported with TBRS and AML are too few to either accurately quantify the risk of AML in TBRS or determine whether this risk is influenced by the underlying DNMT3A genotype. Further studies are required to address this.
The majority of individuals with TBRS are healthy and do not require intensive clinical follow up. However, our practice is to inform families and paediatricians of the possible TBRS complications of behavioural/psychiatric issues, kyphoscoliosis and afebrile seizures to introduce a low threshold for their investigation and/or management. In addition, we undertake a baseline echocardiogram at initial diagnosis to investigate cardiac anomalies detectable on ultrasound scan and frequently refer patients to physiotherapy to evaluate the degree of hypotonia and/or joint hypermobility and to determine whether targeted exercises may be beneficial. Finally, in the absence of evidence-based surveillance protocols for haematological malignancies, we advise clinical vigilance for symptoms possibly related to a haematological malignancy such as easy bruising, recurrent bleeding from gums or nosebleeds, persistent tiredness and recurrent infections.
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